5 Developments in the Pipeline at Seattle Children’s Research Institute

Dr. Jim Hendricks, president of Seattle Children’s Research Institute.

Ranked as one of the top pediatric research centers in the U.S., Seattle Children’s Research Institute has accomplished so much in its 11-year history, and there is much to look forward to in 2018. Here, Dr. Jim Hendricks, president of Seattle Children’s Research Institute shares with On the Pulse what’s in store for the year ahead.  

1. Cancer immunotherapy

Seattle Children’s continued immunotherapy work is going to be very exciting this year.

In 2017, Seattle Children’s opened three new clinical trials offering innovative chimeric antigen receptor (CAR) T-cell immunotherapies for children and young adults with relapsed or refractory acute lymphoblastic leukemia. Currently, there are four Pediatric Leukemia Adoptive Therapy clinical trials underway at Seattle Children’s (PLAT-02, PLAT-03, PLAT-04 and PLAT-05), with others expected to open this year. Read full post »

Seattle Children’s Research Institute’s Top Accomplishments of 2014

Hendricks Headshot 2

Now that the halls have been decked and the most wonderful time of the year is over, Dr. Jim Hendricks, president of Seattle Children’s Research Institute, took down the holiday tinsel from his work station and spent a moment reflecting on the research institute’s greatest accomplishments of 2014.

There were so many exciting developments over the past year that it’s impossible to fit them all in one short list, but here are some outstanding achievements that come to mind.

  • Our investigators had an incredibly successful year when it comes to funding, including government, nonprofit and industry sources. Our total funding increased from $76 million in fiscal year 2013 to nearly $92 million in fiscal year 2014, which represents a 21% increase. This success is a testament to the talent of our investigators considering that the competition for federal grants has increased steadily as the available federal funding has decreased. This funding will help us get closer to finding more treatments and cures for pediatric diseases.
  • We continued our first T cell cancer immunotherapy clinical trial this year and opened enrollment for two additional trials. This ground-breaking therapy reprograms the body’s infection-fighting T cells to find and destroy cancer cells with minimal side effects. While our first trial, PLAT-01, continues treating patients with relapsed leukemia, a second trial treating leukemia patients with T cell immunotherapy has had great success thus far. Additionally, a new trial opened in November to treat neuroblastoma using immunotherapy.

Read full post »